Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Solaya MD vs telos rx

Solaya MD
Graded #255

Lower grade

vs+21.1
telos rx
Graded #8

Higher grade

The verdict

telos rx takes it — 85.4/100 to 64.3/100.

telos rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified, HIPAA telehealth with one of the deepest published catalogs in the ranking — compounded semaglutide and tirzepatide (oral and microdosed routes included) alongside PT-141, intranasal NAD+, and a long recovery/GH peptide bench — with compounded GLP-1 starting from $49/mo on an annual plan.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuetelos rx +42
45
87
Dose & formulationtelos rx +15
75
90
Clinical oversighttelos rx +11
73
84
Labs & monitoringtelos rx +28
52
80
Fulfillmenttelos rx +1
86
87
Contract termstelos rx +13
67
80
Solaya MD · left bartelos rx · right bar

The numbers

MetricSolaya MDtelos rx
WeighScore64.3/10085.4/100
GradeCB
Scorecard rank#255#8
SemaglutideNot disclosed$99/mo injectable — the $49 headline is only the FIRST month of the 12-month prepaid ORAL plan, which renews at $129/mo billed every 48 weeks
TirzepatideNot disclosed$139/mo injectable · $129/mo oral · $116/mo microdosed (microdosing is tirzepatide, not semaglutide)
CoverageAll 50 statesNot publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Solaya MD

Graded #255 · C

Strengths

  • Names its dispensing pharmacy, VialsRX, with a street address and a phone number
  • Names a medical director with an NPI number and the medical practice behind him
  • Runs oral and injectable routes plus a microdose lane, and lists peptide products beside them
  • States service in all 50 U.S. states through affiliated providers and licensed pharmacies

Where it loses points

  • No drug-scoped price is published. The single visible figure, “pricing starts at $185”, names no molecule, no dose and no billing cycle
  • Every figure that does carry a cycle sits behind a create-account gate on a separate questionnaire domain
  • Two different medical directors are named for the same service — one on the About page, another in the FAQ and Terms
  • The medical group is spelled two different ways in two legal documents, as an LLC in one and a professional association in the other
  • Subscription payments are non-refundable, with no partial refunds
  • No compounding class is stated for VialsRX
  • Additional service fees appear in the terms of a testosterone program the site does not otherwise market
telos rx

Graded #8 · B

Strengths

  • Deep published catalog — sema, tirz, PT-141, intranasal NAD+, recovery/GH peptides, GHK-Cu, Dihexa, HRT
  • Needle-free and oral GLP-1 options, not injection-only
  • LegitScript-certified and HIPAA, with US providers and pharmacies, HSA/FSA and free shipping
  • Low GLP-1 entry — from $49/mo microdosed on an annual plan

Where it loses points

  • Everything is compounded and not FDA-approved, including the peptides
  • Pricing is opaque outside GLP-1 and the lowest rates require annual lock-in
  • No named clinicians and thin third-party reviews
  • Several research-grade peptides carry limited clinical evidence

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 536 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard